SOURCE: Edwards Lifesciences

Edwards Lifesciences

September 15, 2010 13:15 ET

Results From The PARTNER Trial Scheduled for Presentation at Upcoming TCT 2010

IRVINE, CA--(Marketwire - September 15, 2010) -  Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that results from The PARTNER Trial Cohort B will be presented at 11 a.m. on Thursday, September 23, at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C. 

The PARTNER Trial is the world's first randomized clinical trial of a transcatheter heart valve and is studying the Edwards SAPIEN heart valve. Cohort B compares the Edwards SAPIEN valve to treatment with medical management in inoperable patients. The Edwards SAPIEN transcatheter valve is an investigational device in the U.S. and not yet available commercially in this country.

About Edwards Lifesciences
Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that enable them to save and enhance lives. Additional company information can be found at www.edwards.com

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements can sometimes be identified by the use of words such as "may," "will," "should," "anticipate," "believe," "plan," "project," "estimate," "expect," "intend," or other similar expressions and include, but are not limited to, the timing and progress of clinical studies relating to the company's transcatheter heart valve technologies and the market opportunity for these technologies. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement.

Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Factors that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements are detailed in the company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2009.

Edwards is a trademark of Edwards Lifesciences Corporation. Edwards Lifesciences, the stylized E logo and Edwards SAPIEN are trademarks of Edwards Lifesciences Corporation and are registered in the United States Patent and Trademark Office.

Contact Information

  • Media Contact:
    Sarah Huoh or Janet Kim
    949-250-5070

    Investor Contact:
    David K. Erickson
    949-250-6826